Get started
Author

Zoltán Polányi

Observed names: Z. Polanyi, Z. Polányi, Zoltan Polanyi
OpenAlex ID: A5008333114
Revising Incidence and Mortality of Lung Cancer in Central Europe: An Epidemiology Review From Hungary
2019 · Krisztina Bogos, Zoltán Kiss, et al. · Frontiers in Oncology · 36
PDF
Age and Gender Specific Lung Cancer Incidence and Mortality in Hungary: Trends from 2011 Through 2016
2021 · Lilla Tamási, Krisztian Horvath, et al. · Pathology & Oncology Research · 27
PDF
Changing Trends in Melanoma Incidence and Decreasing Melanoma Mortality in Hungary Between 2011 and 2019: A Nationwide Epidemiological Study
2021 · Gabriella Liszkay, Zoltan Kiss, et al. · Frontiers in Oncology · 23
PDF
Lung Cancer in Hungary
2020 · Krisztina Bogos, Zoltán Kiss, et al. · Journal of Thoracic Oncology · 17
PDF
Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016
2021 · Krisztina Bogos, Zoltan Kiss, et al. · Pathology & Oncology Research · 13
PDF
Opposite trends in incidence of breast cancer in young and old female cohorts in Hungary and the impact of the Covid-19 pandemic: a nationwide study between 2011–2020
2023 · Zoltán Kiss, Judit Kocsis, et al. · Frontiers in Oncology · 11
Significant Regional Differences in Lung Cancer Incidence in Hungary: Epidemiological Study Between 2011 and 2016
2021 · Gabriella Gálffy, Aladár Vastag, et al. · Pathology & Oncology Research · 9
Significant improvement in melanoma survival over the last decade: A Hungarian nationwide study between 2011 and 2019
2023 · Gabriella Liszkay, Angela Benedek, et al. · Journal of the European Academy of Dermatology and Venereology · 8
PDF
Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic
2023 · Zoltán Kiss, Gabriella Gálffy, et al. · Frontiers in Oncology · 7
Improving Quality Indicator of Melanoma Management – Change of Melanoma Mortality-to-Incidence Rate Ratio Based on a Hungarian Nationwide Retrospective Study
2021 · Máté Várnai, Zoltán Kiss, et al. · Frontiers in Oncology · 6
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data
2016 · Istvan Majer, Gijs van de Wetering, et al. · Applied Health Economics and Health Policy · 6
Increase in the Length of Lung Cancer Patient Pathway Before First-Line Therapy: A 6-Year Nationwide Analysis From Hungary
2021 · Zoltan Kiss, Krisztina Bogos, et al. · Pathology & Oncology Research · 5
PDF
Underlying reasons for post-mortem diagnosed lung cancer cases – A robust retrospective comparative study from Hungary (HULC study)
2022 · Zolta´n Kiss, Krisztina Bogos, et al. · Frontiers in Oncology · 3
PDF
[Novel approaches to the epidemiology of lung cancer in Hungary].
2020 · Krisztina Bogos, Zoltán Kiss, et al. · PubMed · 3
Improvement in lung cancer survival: Six-year survival analysis of patients diagnosed between 2011 and 2016 in Hungary.
2020 · Krisztina Bogos, Zoltan Kiss, et al. · Journal of Clinical Oncology · 1
Type 2 diabetes, cardiovascular disease and chronic kidney disease in Hungary: multimorbidity and 11-year survival in a nationwide retrospective study
2026 · Judit Annamaria Somogyi, Zoltán Vokó, et al. · BMJ Open
Underlying reasons for post-mortem diagnosed lung cancer cases – A robust retrospective comparative study from Hungary (HULC study)
2022 · Zoltán Kiss, Krisztina Bogos, et al. · medRxiv
PDF
45P Analysis of lung cancer patient pathway: A 6-year nationwide analysis from Hungary
2021 · K. Bogos, G. Gaffly, et al. · Journal of Thoracic Oncology
PDF
Age and gender specific lung cancer incidence and mortality in Hungary: Trends from 2011 through 2016.
2020 · Gabriella Galffy, Zoltan Kiss, et al. · Journal of Clinical Oncology
PDF
Everolimus Plus Exemestane Compared to Exemestane and Fulvestrant for the Treatment of ER+ HER2- Metastastic Breast Cancer in the United Kingdom – A Societal Perspective
2014 · Z. Polanyi, P. Dale, et al. · Value in Health
PDF
A Cost Effectiveness Analysis of Everolimus Plus Exemestane Compared to Chemotherapy Agents for the Treatment of ER+ HER2- Metastastic Breast Cancer in the United Kingdom
2014 · Z. Polanyi, P. Dale, et al. · Value in Health
Kokszoló kemencék tüzeléstechnikai vizsgálata
2006 · Krisztián Horváth, Zoltán Polányi, et al. · Fiatal Műszakiak Tudományos Ülésszaka
PDF
Works count: 22
Citation count: 175
H-index: 8
I10-index: 6
Year
Topic
Type